Back to Research Hub
Exelixis, Inc.
EXEL
$52.99+1.25 (+2.42%)
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States.
StreetsValue research for Exelixis, Inc. (EXEL)
Members get the full report for Exelixis, Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.